No Data
No Data
Immutep Announces First Participant Dosed In Phase I Study Of IMP761
Immutep Doses First Participant in In-Human Trial of Antibody Therapy for Autoimmune Diseases
Immutep to Participate in Upcoming Investor Conferences
Immutep Advances LAG-3 Immunotherapy Trials
Immutep Ltd Advances Cancer Immunotherapy Trials
ImpediMed Target Price Cut 12% to A$0.18/Share by Wilsons>IMM.AU
No Data